Ingredienti del ginseng

Ginsenoside-Rg3, possess an ability to inhibit the lung metastasis of tumor cells, and the mechanism of their antimetastatic effect is related to inhibition of the adhesion and invasion of tumor cells, and also to anti-angiogenesis activity.

Ginsenoside Rb3 has anti-myocardial ischemia-reperfusion injury, neuroprotective, antidepressant-like, and antioxidant effects, it also possesses the potential of the clinical use in preventing and treating diabetes. Ginsenoside Rb3 significantly attenuates the changes of creatine kinase activity and lactate dehydrogenase activity, exhibits inhibitory effect on TNFα-induced NF-κB transcriptional activity with an IC50 of 8.2 μM in 293T cell lines, it also inhibits the induction of COX-2 and iNOS mRNA.

Ginsenoside Rh3 is a bacterial metabolite of Rg5, which is the main constituent of heat-processed ginseng, has anti-inflammatory effect in microglia by modulating AMPK and its downstream signaling pathways.

Ginsenoside Rk1, one of the main elements of Sung Ginseng, has been confirmed as a new endothelial barrier enhancer recently and has anti-cancer activity, the mechanism involves coordination between inhibition of telomerase activity and induction of apoptosis.

Ginsenoside Rc (Rc), a protopanaxadiol type ginsenoside, is the active component mainly responsible for the therapeutic and pharmacologic properties of ginseng, which are derived from its suppression of superoxide-induced free radicals, Rc can modulate Forkhead box O (FoxO1)phosphorylation through activation of PI3K/Akt and inhibition of AMPK and FoxO1 acetylation through interaction with CBP and SIRT1, and that this leads to upregulation of catalase under conditions of oxidative stress.

Ginsenoside Rd (Rd), a saponin isolated from the roots of panax notoginseng, Rd has immunological adjuvant activity, and elicits a Th1 and Th2 immune response by regulating production and gene expression of Th1 cytokines and Th2 cytokines.

Ginsenoside (G)-F1 is an enzymatic metabolite generated from G-Rg1, it has been reported to suppress platelet aggregation and to reduce gap junction-mediated intercellular communication, also as a novel anti-skin cancer drug with anti-proliferative and anti-migration features.

Ginsenoside Rg5 plays a novel role as an IGF-1R agonist, promoting therapeutic angiogenesis and improving hypertension without adverse effects in the vasculature, it can ameliorate lung inflammation possibly by inhibiting the binding of LPS to toll-like receptor (TLR)-4 on macrophages. Ginsenoside Rg5 blocks cell cycle of SK-HEP-1 cells at the Gl/S transition phase by down-regulating cyclin E-dependent kinase activity and that the down-regulation of cyclin E-dependent kinase activity is caused mainly by induced CDK2 inhibitor, p21Cip/WAF1 and decreased levels of cyclin E.

(20R)-Ginsenoside Rh1 exhibits various pharmacological activities including vasorelaxation, antioxidation, anti-inflammation, and anticancer.